Core Insights - Edwards Lifesciences and Boston Scientific both demonstrated strong quarterly performance, indicating robust demand in the heart device market [1] Company Strategies - Edwards Lifesciences and Boston Scientific are employing fundamentally different strategies within the heart device sector, which may impact their future growth trajectories [1]

Analysts on Wall Street project that Edwards Lifesciences (EW) will announce quarterly earnings of $0.62 per share in its forthcoming report, representing an increase of 5.1% year over year. Revenues are projected to reach $1.54 billion, increasing 11.1% from the same quarter last year.The consensus EPS estimate for the quarter has undergone an upward revision of 0.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial e ...

Key Takeaways EW is set to report Q4 2025 results on Feb. 10, with revenues expected to rise 11.1% year over year. EW's TAVR segment is expected to benefit from global procedure growth and higher sales guidance for 2025. EW's TMTT arm is projected to post 44.2% sales growth, aided by traction in PASCAL, EVOQUE and SAPIEN M3.Edwards Lifesciences Corp. (EW) is scheduled to report fourth-quarter 2025 results on Feb. 10, after market close.In the last reported quarter, the company’s adjusted earnings per share ...

2月2日，国家药监局器械技术审评中心公示2026年第三批创新医疗器械特别审查申请审查结果，又有10款创新产品获准创新医疗器械特别审查程序。 以下本次进入创新通道的10款创新产品： 1.产品名称：慢性阻塞性肺部疾病辅助评估软件 申 请 人：波江生命科学（上海）有限公司 2.产品名称：超声治疗仪 申 请 人：深圳腾复医疗科技有限公司 3.产品名称：经导管人工三尖瓣瓣膜 申 请 人：爱德华兹生命科学有限责任公司 4.产品名称：经导管人工三尖瓣瓣膜 申 请 人：江苏臻亿医疗科技有限公司 5.产品名称：超声溶栓导管及支架系统 申 请 人：上海腾复医疗科技有限公司 6.产品名称：放射治疗计划软件 申 请 人：国科离子医疗科技有限公司 7.产品名称：植入式心律转复除颤器 申 请 人：创领心律管理医疗器械（上海）有限公司 8.产品名称：外周球扩覆膜支架系统 申 请 人：浙江归创医疗科技有限公司 9.产品名称：胸腹腔内窥镜手术系统 申 请 人：直观医疗公司 10.产品名称：冠状静脉窦球囊反搏系统 申 请 人：上海微创旋律医疗科技有限公司 本文为转载发布，仅做分享，文章中观点仅代表原平台作者观点，与本平台无关。如若本文有与贵平台 ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2025 after the market closes on Tuesday, February 10, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations†section of the Edwards website at ir.edwards.com. About Edwards Li. ...

We came across a bullish thesis on Edwards Lifesciences Corporation on R. Dennis’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on EW. Edwards Lifesciences Corporation's share was trading at $81.49 as of January 29th. EW’s trailing and forward P/E were 35.90 and 28.82 respectively according to Yahoo Finance. Olema (OLMA) Hits 4-Year High as Jefferies Hikes PT Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the U ...

Edwards Lifesciences to Present at the TD Cowen 46th Annual Health Care ConferenceFeb 2, 2026 7:05 AM Eastern Standard Time# Edwards Lifesciences to Present at the TD Cowen 46th Annual Health Care ConferenceShare---IRVINE, Calif.--([BUSINESS WIRE])--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 46th Annual Health Care Conference on Monday, Mar. 2, 2026.Scott Ullem, chief financial officer, is scheduled to present at 9:50 a.m. ET. A live webcast of the presen ...

Group 1 - Edwards Lifesciences Corporation (NYSE:EW) is considered one of the best healthcare stocks to buy for 2026, with Stifel raising its price target to $110 from $105 while maintaining a Buy rating [1] - The price target increase is attributed to a significant rise in Transcatheter Aortic Valve Replacement (TAVR) procedures, indicating strong growth in the TAVR market fundamentals [2] - The company's revenue grew by 10% in the third quarter, primarily driven by the TAVR division, which constitutes 75% of total revenue, marking the strongest growth for this division in recent years [2] Group 2 - On January 9, TD Cowen upgraded Edwards Lifesciences to a Buy from Hold and raised the price target to $97 from $90, citing a renewed growth cycle driven by expanded indications for TAVR [3] - Edwards Lifesciences is a medical technology company focused on innovations for heart conditions, specializing in structural heart disease and critical care monitoring [4]

Edwards Lifesciences (NYSE:EW) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds. On January 20, Adam Maeder from Piper Sandler maintained his Overweight rating on Edwards Lifesciences (NYSE:EW). The analyst also adjusted his price target on the stock from $95 to $98, which now yields almost 20% upside. Why Core Scientific Inc. (CORZ) Performed Worst On Tuesday? goodluz/Shutterstock.com Maeder’s revision came after Piper Sandler made adjustments to some of its forecast ...

Core Insights - Wedgewood Partners anticipates stronger market volatility in the coming years and has moderated its enthusiasm for investments [1] - The Wedgewood Composite returned -1.8% in Q4 2025, underperforming compared to the S&P 500's 2.7% and other indices [1] - The firm attributes its underperformance to poor stock selection, valuation corrections of past performers, and being underweight in AI stocks [1] Company Focus: Edwards Lifesciences Corporation - Edwards Lifesciences Corporation (NYSE:EW) is highlighted for its products and technologies for structural heart disease and critical care monitoring [2] - As of January 16, 2026, Edwards Lifesciences stock closed at $84.35, with a one-month return of -2.52% and a 52-week gain of 20.88% [2] - The company has a market capitalization of $49.522 billion [2] Performance and Growth Potential - Edwards Lifesciences contributed positively to Wedgewood's performance during the quarter, presenting favorable seven-year data for its transcatheter aortic valves [3] - The company is expected to drive double-digit earnings growth over the next few years, as its long-term data evolves standards of care [3] Hedge Fund Interest - Edwards Lifesciences is not among the 30 most popular stocks among hedge funds, with 64 hedge fund portfolios holding the stock at the end of Q3 2025 [4] - While the potential of Edwards Lifesciences is acknowledged, certain AI stocks are considered to offer greater upside potential and less downside risk [4]